Cline Scientific: Communiqué from the Annual General Meeting
Today, 18 June, 2024, the Annual General meeting of Cline Scientific AB, 556867-8238, ("Cline Scientific" or the "Company") was held. Below is a summary of the decisions that were made. All decisions were made with the required majority.
Decision on the following:
Determination of the income statement and the balance sheet
The profit and loss statement and balance sheet were approved by the meeting.
Dispositions regarding the company's profit or loss according to the established balance sheet
The meeting decided that the company's accumulated loss is balanced in a new account and that there will be no dividend for the financial year 2023.
Exemption from liability for the board members and the CEO
The meeting granted the board members and the CEO discharge from liability for the past year.
Determining the number of board members, deputies and auditors
The number of board members was determined to be three and no deputies and one auditor with a deputy.
Determining the fees for the board and the auditors
The meeting decided that the company's auditor should receive a fee according to an approved bill. The board is not remunerated.
Election of the board and election of the auditor
The meeting re-elected the following sitting board members: Karl Corneliusson, Hanne Evenbratt and Patrik Sundh. Karl Corneliusson was elected chairman of the company's board. Johan Bjurquist and Andreas Regell have declined re-election.
Authorized accountant Stefan Kylebäck was elected as auditor. Authorized accountant Markus Hellsten was elected as deputy auditor.
Authorization for the board to make decisions on the issue of shares, convertible loans and/or warrants
The meeting decided to adopt the board's proposal for authorization stated in the notice. The decision was approved by at least two-thirds of both the votes cast and the shares represented at the meeting.
Determination of change in the Articles of Association: Change in limits for number of shares, share capital and number of members on the board
The meeting decided that the limits for the number of shares are set to: Minimum number of shares 38,000,000 and maximum number of shares 152,000,000 and that the limits for share capital are set to: Minimum SEK 3,800,000 and maximum SEK 15,200,000.
The meeting decided that the number of board members should be changed to a minimum of three and a maximum of six members.
Determining minor adjustments
The meeting decided the board, or the person appointed by the board, shall have the right to make the minor adjustments to the above decision that may prove necessary in connection with registration at the Swedish Companies Registration Office.
Closing of the meeting
The meeting is closed by the chairman of the meeting, Johan Bjurquist.
The company is listed on the Nasdaq First North Growth Market. Redeye AB is Cline Scientific's Certified Adviser. The information was submitted for publication via the contact person listed above at 19:00 CEST on 18 June 2024.
For more information, please contact:
Patrik Sundh, CEO
Email: patrik.sundh@clinescientific.com
Phone: +46 703-585 088
Cline Scientific AB (publ)
Pepparedsleden 1
AstraZeneca BioVentureHub Email: info@clinescientific.com
431 53 MÖLNDAL Website: www.clinescientific.com
About Cline Scientific
Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. Cline’s unique patented surface nanotechnology provides solutions to critical challenges for cell-based products and process in Life Science. Cline is driving two projects through to a clinical stage, StemCART - a stem cell therapy for joint repair, and CellRACE- a cancer diagnostic to predict metastasis.